

# **Coal India**

# **Result Update**



Your success is our success

Refer to important disclosures at the end of this report

# Strong all-round performance; maintain Buy

**CMP** Rs 223 as of (February 12, 2019)

**Target Price** Rs 289 (▼)

-/-

(13)

12

BUY

21.9

Rating **Upside** BUY (■) 29.5 %

- Coal India reported strong all-round performance, driven by strong FSA as well as Eauction realization, and significantly lower-than-expected RM consumption.
- Revenue at Rs250bn (up 16% yoy/up 13% qoq) was driven by yoy/qoq growth of 13%/2% in the FSA realization. The blended realization at Rs1,517/t was also up yoy/qoq basis by
- Overall costs remained under control due to lower-than-expected RM costs driving down the sequential cost per ton by 9.1% to Rs1,264/t.
- We have modelled Rs22/share dividend, in line with its past dividend track record, implying a 10% dividend yield at the CMP. We value the stock at 6x FY20E EV/EBITDA. Maintain Buy with TP of Rs 289.
- Both production of 156mt (yoy up 3%, qoq up 30%) and dispatches of 154 mt (up 1% yoy, up 12% goq) were in line with expectations. FSA sales at 136mt (up 11% yoy, up 16% goq) overshadowed the E-auction sales which were down by 43% on a yoy basis and down 10% sequentially.
- For the period Apr-Dec'18, coal production at 412.44mt was up 7.4%, while dispatches at 444.63mt was higher by 5.5% on yoy basis.
- Excluding the OBR provision, EBITDA/t at Rs518 was higher 42.5% on a yoy basis and 50.8% on qoq basis.
- We believe that on a long-term basis, continued restriction on evacuation will limit the overall potential of the company. However, given the strong cash flows, we expect the company to declare strong dividends going forward.
- At the CMP of Rs 223, we build in 10% dividend yield and believe that the stock is attractively priced at current levels. We value Coal India at 6x FY20E EV/EBITDA. Maintain Buy.

## **Change in Estimates** EPS Chg FY19E/FY20E (%) Target Price change (%) Target Period (Months) Previous Reco **Emkay vs Consensus EPS Estimates** FY19E FY20E

**Fmkay** 

Consensus


Consensus	20.0	20.0
Mean Consensus TP (12N	<b>1</b> )	Rs 314
Stock Details		
Bloomberg Code	С	OAL IN
Face Value (Rs)		10
Shares outstanding (mn)		6,207
52 Week H/L	3	17 / 214
M Cap (Rs bn/USD bn)	1,384	/ 19.56
Daily Avg Volume (nos.)	6,0	068,472
Daily Avg Turnover (US\$ r	mn)	20.7

23.1

Shareholding Pattern Dec 18						
Promoters	72.9%					
FIIs	6.0%					
DIIs	17.6%					
Public and Others	3.5%					

Price Performance										
(%)	1M	3M	6M	12M						
Absolute	(4)	(16)	(19)	(26)						
<b>Rel. to Nifty</b> (4) (18) (15) (28)										

Relative price chart



Source: Bloomberg

This report is solely produced by Emkay Global. The following person(s) are responsible for the production of the recommendation:

#### Vishal Chandak

vishal.chandak@emkayglobal.com

+91 22 6612 1275

### Kamal Kanta Sahoo

kamal.sahoo@emkayglobal.com +91 22 6612 1244

#### Financial Snapshot (Consolidated)

(Rs mn)	FY16	FY17	FY18	FY19E	FY20E
Revenue	794,204	798,631	858,624	956,408	1,038,342
EBITDA	187,113	122,830	169,507	219,501	221,039
EBITDA Margin (%)	23.6	15.4	19.7	23.0	21.3
APAT	142,679	92,800	144,042	143,652	135,901
EPS (Rs)	22.6	14.9	23.2	23.1	21.9
EPS (% chg)	4.0	(33.8)	55.2	(0.3)	(5.4)
ROE (%)	38.4	29.7	52.6	57.5	60.2
P/E (x)	9.9	14.9	9.6	9.6	10.2
EV/EBITDA (x)	5.5	8.5	6.3	5.5	5.5
P/BV (x)	4.2	4.8	5.3	5.8	6.5

Source: Company, Emkay Research

## Exhibit 1: Actual vs Estimates (Q3FY19)

Rs mn	Actual	Estimate	Consensus Estimate	% vari	ation	Comment
KS IIIII	Actual	(Emkay)	(Bloomberg)	Emkay	Consensus	Comment
Total Revenue	250458	244,490	238,275	2.4	5.1	
EBITDA	67878	54,636	50,150	24.2	35.3	Revenue in-line, EBITDA beat driven by lower
EBITDA Margin (%)	27.1	22.3				RM cost, PAT beat driven by better than expected EBITDA.
Emkay Net profit	45657	40,629	38,447	12.3	18.8	

Source: Company, Emkay Research

## **Exhibit 2: Quarterly Financials**

Rs mn	Q3FY18	Q2FY19	Q3FY19	YoY (%)	QoQ (%)	YTDFY19	YTDFY18	YoY (%)
Revenue	216,433	221,981	250,458	15.7	12.8	715,048	589,533	21.3
Expenditure	(170,254)	(182,838)	(182,580)	7.2	(0.1)	(550,703)	(495,825)	11.1
as % of sales	78.7	82.4	72.9			77.0	84.1	
Consumption of RM	(23,023)	(29,937)	(19,358)	(15.9)	(35.3)	(76,669)	(77,395)	(0.9)
as % of sales	10.6	13.5	7.7			10.7	13.1	
Employee Cost	(87,532)	(89,535)	(95,176)	8.7	6.3	(280,693)	(259,797)	8.0
as % of sales	40.4	40.3	38.0			39.3	44.1	
Other expenditure	(59,700)	(63,366)	(68,046)	14.0	7.4	(193,341)	(158,632)	21.9
as % of sales	27.6	28.5	27.2			27.0	26.9	
EBITDA	46,179	39,142	67,878	47.0	73.4	164,345	93,708	75.4
Depreciation	(7,511)	(8,069)	(8,611)	14.6	6.7	(24,132)	(21,356)	13.0
EBIT	38,668	31,074	59,267	53.3	90.7	140,213	72,352	93.8
Other Income	8,409	20,113	11,633	38.3	(42.2)	43,846	26,582	64.9
Interest	(974)	(8)	(620)	(36.4)	7,549.4	(1,731)	(3,191)	(45.7)
PBT	46,102	51,178	70,281	52.4	37.3	182,328	95,743	90.4
Total Tax	(16,052)	(20,317)	(24,623)	53.4	21.2	(67,966)	(38,487)	76.6
Adjusted PAT	30,050	30,861	45,657	51.9	47.9	114,362	57,256	99.7
(Profit)/loss from JV's/Ass/MI	1	(14)	11			18	(4)	
Adj.PAT after MI	30,051	30,847	45,668	52.0	48.0	114,380	57,252	99.8
Extra ordinary items	-	-	-			-	-	
Reported PAT	30,051	30,847	45,668	52.0	48.0	114,380	57,252	99.8
Reported EPS	4.84	4.97	7.36	52.0	48.0	18	9	99.8

Margins (%)				(bps)	(bps)			(bps)
EBIDTA	21	18	27	+577 bps	+947 bps	23.0	15.9	+709 bps
EBIT	17.9	14.0	23.7	+580 bps	+967 bps	19.6	12.3	+734 bps
EBT	21.3	23.1	28.1	+676 bps	+501 bps	25.5	16.2	+926 bps
PAT	13.9	13.9	18.2	+435 bps	+433 bps	16.0	9.7	+628 bps
Effective Tax rate	34.8	39.7	35.0	+22 bps	-466 bps	37.3	40.2	-292 bps

Source: Company, Emkay Research

Emkay Research is also available on www.emkayglobal.com, Bloomberg EMKAY<GO>, Reuters and DOWJONES. DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd, its respective connected and associated corporations and affiliates are the distributors of the research reports, please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore

**Exhibit 3: Segment Financials** 

Volume	Q3FY18	Q2FY19	Q3FY19	YoY (%)	QoQ (%)	YTDFY19	YTDFY18	YoY (%)
Dispatch	152	137	154	0.9	12.0	291	269	8.1
FSA	122	117	136	11.4	16.3	247	212	16.7
E-Auction	26.4	17.7	14.7	(44.4)	(17.1)	37	51	(26.6)
Total Washed Coal	2.8	2.4	2.9	5.0	19.7	5	6	(10.3)
Total	152	138	154	1.6	12.0	291	269	8.0
Production	152	120	156	2.6	30.4	256	232	10.6
Production	152	137	154	0.9	12.0	291	269	8.1
Realization								
FSA	1,182	1,308	1,334	12.9	2.0	1,311	1,212	8.1
E-Auction	1,998	2,592	2,847	42.5	9.8	2,491	1,599	55.8
Total Washed Coal	2,975	2,602	2,866	(3.6)	10.1	2,513	3,103	(19.0)
Total	1,365	1,505	1,517	11.1	0.8	1,490	1,334	11.7
Segmental Revenue								
FSA	144,000	152,840	181,250	25.9	18.6	324,000	256,720	26.2
E-Auction	52,680	45,830	41,710	(20.8)	(9.0)	92,400	80,820	14.3
Total Washed Coal	8,270	6,350	8,370	1.2	31.8	12,540	17,250	(27.3)
Total Revenue	207,080	207,120	233,830	12.9	12.9	433,100	359,120	20.6

Source: Company, Emkay Research

Exhibit 4: Volume & Realization

Volume & Realization	Q3FY18	Q2FY19	Q3FY19	YoY (%)	QoQ (%)	YTDFY19	YTDFY18	YoY (%)
FSA (mt)	122	117	136	11.4	16.3	383	334	14.8
Realisation Rs/t	1,182	1,308	1,334	12.9	2.0	1,319	1,201	9.8
E-auction (mt)	26	18	15	(44.4)	(17.1)	52	77	(32.7)
Realisation Rs/t	1,998	2,592	2,847	42.5	9.8	2,592	1,736	49.3
Washed coal(mt)	2.8	2.4	2.9	5.0	19.7	8	8	(5.2)
Realisation Rs/t	2,975	2,602	2,866	(3.6)	10.1	2,643	3,060	(13.6)
Other By-product(mt)	2	0.9	2	0.0	122.2	4	4	0.0
Realisation Rs/t	2,782	2,782	2,782	-	-	2,782	2,782	-
Total Production(mt)	152.1	119.6	156.0	2.6	30.4	412	384	7.4
Total Dispatches(mt)	152.4	137.3	153.8	0.9	12.0	445	421	5.5
Avg Realisation Rs/t	1,365.2	1,505.3	1,517.2	11.1	0.8	1,500	1,345	11.5

Source: Company, Emkay Research

Emkay Research is also available on www.emkayglobal.com, Bloomberg EMKAY<GO>, Reuters and DOWJONES. DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd, its respective connected and associated corporations and affiliates are the distributors of the research reports, please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore

## **Key Financials (Consolidated)**

## **Income Statement**

Y/E Mar (Rs mn)	FY16	FY17	FY18	FY19E	FY20E
Revenue	794,204	798,631	858,624	956,408	1,038,342
Expenditure	607,091	675,801	689,118	736,907	817,303
EBITDA	187,113	122,830	169,507	219,501	221,039
Depreciation	28,259	29,091	30,664	36,556	42,203
EBIT	158,854	93,739	138,843	182,945	178,836
Other Income	59,406	54,818	46,583	45,130	37,166
Interest expenses	3,862	4,097	4,318	4,318	4,318
PBT	214,398	144,460	181,108	223,758	211,684
Tax	71,719	51,660	37,067	80,105	75,783
Extraordinary Items	0	0	(73,844)	0	0
Minority Int./Income from Assoc.	0	0	0	0	0
Reported Net Income	142,679	92,800	70,198	143,652	135,901
Adjusted PAT	142,679	92,800	144,042	143,652	135,901

## **Balance Sheet**

Y/E Mar (Rs mn)	FY16	FY17	FY18	FY19E	FY20E
Equity share capital	63,164	62,074	62,074	62,074	62,074
Reserves & surplus	275,812	224,085	199,832	175,411	152,308
Net worth	338,976	286,159	261,906	237,485	214,382
Minority Interest	1,048	3,446	3,446	3,446	3,446
Loan Funds	11,921	2,968	2,968	2,968	2,968
Net deferred tax liability	(20,445)	(26,108)	(26,108)	(26,108)	(26,108)
Total Liabilities	331,499	266,466	242,212	217,791	194,688
Net block	205,494	250,647	309,983	423,427	461,224
Investment	29,019	46,635	51,299	56,429	62,072
Current Assets	810,183	794,735	769,735	688,819	729,889
Cash & bank balance	383,128	345,722	310,863	177,689	172,126
Other Current Assets	133,356	142,366	153,061	170,492	185,098
<b>Current liabilities &amp; Provision</b>	750,252	825,551	888,804	950,883	1,058,496
Net current assets	59,931	(30,816)	(119,069)	(262,064)	(328,607)
Misc. exp	0	0	0	0	0
Total Assets	331,499	266,466	242,213	217,792	194,688

## **Cash Flow**

Y/E Mar (Rs mn)	FY16	FY17	FY18	FY19E	FY20E
PBT (Ex-Other income) (NI+Dep)	154,992	89,642	60,681	178,627	174,518
Other Non-Cash items	0	0	0	0	0
Chg in working cap	(59,994)	59,004	53,394	9,820	60,980
Operating Cashflow	55,400	130,174	111,990	149,216	206,236
Capital expenditure	(61,308)	(39,055)	(90,000)	(150,000)	(80,000)
Free Cash Flow	(5,908)	91,119	21,990	(784)	126,236
Investments	(885)	(17,616)	(4,664)	(5,130)	(5,643)
Other Investing Cash Flow	0	0	0	0	0
Investing Cashflow	(2,787)	(1,853)	(48,080)	(110,000)	(48,477)
Equity Capital Raised	0	(1,090)	0	0	0
Loans Taken / (Repaid)	7,901	(8,952)	0	0	0
Dividend paid (incl tax)	(208,302)	(144,527)	(94,451)	(168,073)	(159,004)
Other Financing Cash Flow	0	0	0	0	0
Financing Cashflow	(204,262)	(158,666)	(98,769)	(172,391)	(163,322)
Net chg in cash	(151,649)	(30,345)	(34,859)	(133,174)	(5,563)
Opening cash position	534,777	376,067	345,722	310,863	177,689
Closing cash position	383,128	345,722	310,863	177,689	172,126

Source: Company, Emkay Research

Emikay Research is also available on www.emikayglobal.com, Bloomberg EMIKAY<GO>, Reuters and DOWJONES. DBS Bank Ltd, DBS Vickers Securities (Singapore) Ple Ltd,its respective connected and associated corporations and affiliates are the distributors of the research reports, please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore

## **Key Ratios**

Profitability (%)	FY16	FY17	FY18	FY19E	FY20E
EBITDA Margin	23.6	15.4	19.7	23.0	21.3
EBIT Margin	20.0	11.7	16.2	19.1	17.2
Effective Tax Rate	33.5	35.8	20.5	35.8	35.8
Net Margin	18.0	11.6	16.8	15.0	13.1
ROCE	60.6	49.7	72.9	99.2	104.7
ROE	38.4	29.7	52.6	57.5	60.2
RoIC	(93.5)	(77.0)	(113.0)	(268.5)	(640.6)

Per Share Data (Rs)	FY16	FY17	FY18	FY19E	FY20E
EPS	22.6	14.9	23.2	23.1	21.9
CEPS	27.1	19.6	28.1	29.0	28.7
BVPS	53.7	46.1	42.2	38.3	34.5
DPS	27.4	19.9	13.0	23.1	21.9

Valuations (x)	FY16	FY17	FY18	FY19E	FY20E
PER	9.9	14.9	9.6	9.6	10.2
P/CEPS	8.2	11.4	7.9	7.7	7.8
P/BV	4.2	4.8	5.3	5.8	6.5
EV / Sales	1.3	1.3	1.3	1.3	1.2
EV / EBITDA	5.5	8.5	6.3	5.5	5.5
Dividend Yield (%)	12.3	8.9	5.8	10.4	9.8

Gearing Ratio (x)	FY16	FY17	FY18	FY19E	FY20E
Net Debt/ Equity	(1.1)	(1.2)	(1.2)	(0.7)	(0.8)
Net Debt/EBIDTA	(2.0)	(2.8)	(1.8)	(0.8)	(8.0)
Working Cap Cycle (days)	(148.5)	(172.1)	(182.8)	(167.8)	(176.0)

Growth (%)	FY16	FY17	FY18	FY19E	FY20E
Revenue	7.3	0.6	7.5	11.4	8.6
EBITDA	8.4	(34.4)	38.0	29.5	0.7
EBIT	6.3	(41.0)	48.1	31.8	(2.2)
PAT	3.9	(35.0)	(24.4)	104.6	(5.4)

Quarterly (Rs mn)	Q3FY18	Q4FY18	Q1FY19	Q2FY19	Q3FY19
Revenue	216,433	269,092	242,609	221,981	250,458
EBITDA	46,179	75,799	57,325	39,142	67,878
EBITDA Margin (%)	21.3	28.2	23.6	17.6	27.1
PAT	30,051	12,943	37,864	30,847	45,668
EPS (Rs)	4.8	2.1	6.1	5.0	7.4

Source: Company, Emkay Research

Shareholding Pattern (%)	Dec-17	Mar-18	Jun-18	Sep-18	Dec-18
Promoters	78.6	78.6	78.3	78.3	72.9
FIIs	5.8	5.5	5.4	5.7	6.0
DIIs	12.2	12.9	13.2	13.0	17.6
Public and Others	3.5	3.1	3.1	3.0	3.5

Source: Capitaline


Emkay Research is also available on www.emkayglobal.com, Bloomberg EMKAY<GO>, Reuters and DOWJONES. DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd, its respective connected and associated corporations and affiliates are the distributors of the research reports, please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore

#### RECOMMENDATION HISTORY TABLE

Date	Closing Price	TP	Period (months)	Rating	Analyst
14-Nov-18	266	333	12m	Buy	Kamal Sahoo
14-Aug-18	283	359	12m	Buy	Goutam Chakraborty
30-May-18	289	359	12m	Buy	Goutam Chakraborty
8-May-18	268	359	12m	Buy	Goutam Chakraborty
1-Mar-18	313	359	12m	Buy	Goutam Chakraborty
12-Feb-18	301	359	12m	Buy	Goutam Chakraborty
11-Jan-18	308	359	12m	Buy	Goutam Chakraborty
13-Nov-17	275	314	12m	Accumulate	Goutam Chakraborty
2-Nov-17	291	314	12m	Accumulate	Goutam Chakraborty
1-Nov-17	287	314	12m	Accumulate	Goutam Chakraborty
12-Oct-17	282	314	12m	Accumulate	Goutam Chakraborty
11-Sep-17	257	279	12m	Accumulate	Goutam Chakraborty
5-Sep-17	254	279	12m	Accumulate	Goutam Chakraborty
16-Aug-17	238	279	12m	Accumulate	Goutam Chakraborty
30-Jun-17	244	279	12m	Hold	Goutam Chakraborty
29-May-17	267	279	12m	Hold	Goutam Chakraborty
2-May-17	275	320	12m	Hold	Goutam Chakraborty
5-Apr-17	290	320	12m	Hold	Goutam Chakraborty
13-Feb-17	321	320	12m	Hold	Goutam Chakraborty
3-Feb-17	326	300	12m	Hold	Goutam Chakraborty
2-Jan-17	300	300	12m	Hold	Goutam Chakraborty
27-Dec-16	289	300	12m	Hold	Goutam Chakraborty
13-Dec-16	306	300	12m	Hold	Goutam Chakraborty
3-Oct-16	328	356	12m	Accumulate	Goutam Chakraborty
15-Sep-16	324	356	12m	Accumulate	Goutam Chakraborty
1-Aug-16	326	384	12m	Buy	Goutam Chakraborty
4-Jul-16	318	384	12m	Buy	Goutam Chakraborty
2-Jun-16	307	384	12m	Buy	Goutam Chakraborty
2-May-16	289	384	12m	Buy	Goutam Chakraborty
2-Mar-16	311	384	12m	Buy	Goutam Chakraborty

Source: Company, Emkay Research

## RECOMMENDATION HISTORY CHART



Source: Bloomberg, Company, Emkay Research

## **Emkay Rating Distribution**

BUY

ACCUMULATE

HOLD

REDUCE

Expected total return (%) (Stock price appreciation and dividend yield) of over 25% within the next 12-18 months.

Expected total return (%) (Stock price appreciation and dividend yield) of over 10% within the next 12-18 months.

Expected total return (%) (Stock price appreciation and dividend yield) of upto 10% within the next 12-18 months.

Expected total return (%) (Stock price depreciation) of upto (-) 10% within the next 12-18 months.

SELL The stock is believed to underperform the broad market indices or its related universe within the next 12-18 months.

Completed Date: 13 Feb 2019 03:19:51 (SGT) Dissemination Date: 13 Feb 2019 03:20:51 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

## GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

- This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.
- Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

Disclaimer for U.S. persons only: This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

Emikay Research is also available on www.emkayglobal.com, Bloomberg EMKAY<GO>, Reuters and DOWJONES. DBS Bank Ltd, DBS Vickers Securities (Singapore) Ple Ltd, its respective connected and associated corporations and affiliates are the distributors of the research report or research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore

ED: ANISH MATHEW SA: DHANANJAY SINHA February 12, 2019 | 7

#### GENERAL DISCLOSURE/DISCLAIMER BY DBS BANK LTD AS DISTRIBUTOR OF THE RESEARCH REPORT

This report is solely intended for the clients of DBS Bank Ltd,its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBS Bank Ltd.

The research set out in this report is based on information obtained from sources believed to be reliable, but we (which collectively refers to DBS Bank Ltd, its respective connected and associated corporations, affiliates and their respective directors, officers, employees and agents (collectively, the "DBS Group") have not conducted due diligence on any of the companies, verified any information or sources or taken into account any other factors which we may consider to be relevant or appropriate in preparing the research. Accordingly, we do not make any representation or warranty as to the accuracy, completeness or correctness of the research set out in this report. Opinions expressed are subject to change without notice. This research is prepared for general circulation. Any recommendation contained in this document does not have regard to the specific investment objectives, financial situation and the particular needs of any specific addressee. This document is for the information of addressees only and is not to be taken in substitution for the exercise of judgement by addressees, who should obtain separate independent legal or financial advice. The DBS Group accepts no liability whatsoever for any direct, indirect and/or consequential loss (including any claims for loss of profit) arising from any use of and/or reliance upon this document and/or further communication given in relation to this document. This document is not to be construed as an offer or a solicitation of an offer to buy or sell any securities. The DBS Group, along with its affiliates and/or persons associated with any of them may from time to time have interests in the securities mentioned in this document. The DBS Group, may have positions in, and may effect transactions in securities mentioned herein and may also perform or seek to perform broking, investment banking and other banking services for these companies. Any valuations, opinions, estimates, forecasts, ratings or risk assessments herein constitutes a judgment as of the date of this report, and there can be no assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments. The information in this document is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed, it may not contain all material information concerning the company (or companies) referred to in this report and the DBS Group is under no obligation to update the information in this report. This publication has not been reviewed or authorized by any regulatory authority in Singapore, Hong Kong or elsewhere. There is no planned schedule or frequency for updating research publication relating to any issuer.

The valuations, opinions, estimates, forecasts, ratings or risk assessments described in this report were based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. It can be expected that one or more of the estimates on which the valuations, opinions, estimates, forecasts, ratings or risk assessments were based will not materialize or will vary significantly from actual results. Therefore, the inclusion of the valuations, opinions, estimates, forecasts, ratings or risk assessments described herein IS NOT TO BE RELIED UPON as a representation and/or warranty by the DBS Group (and/or any persons associated with the aforesaid entities), that: (a) such valuations, opinions, estimates, forecasts, ratings or risk assessments or their underlying assumptions will be achieved, and (b) there is any assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments stated therein. Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets. Any assumptions made in this report that refers to commodities, are for the purposes of making forecasts for the company (or companies) mentioned herein. They are not to be construed as recommendations to trade in the physical commodity or in the futures contract relating to the commodity referred to in this report.

DBSVUSA, a US-registered broker-dealer, does not have its own investment banking or research department, has not participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months and does not engage in marketmaking.

## ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

Emikay Research is also available on www.emkayglobal.com, Bloomberg EMKAY<GO>, Reuters and DOWJONES. DBS Bank Ltd, DBS Vickers Securities (Singapore) Ple Ltd, its respective connected and associated corporations and affiliates are the distributors of the research report or research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore

February 12, 2019 | 8

<sup>1</sup> An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst

<sup>&</sup>lt;sup>2</sup> Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

#### COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of February 12, 2019
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report Disclosure of previous investment recommendation produced:
- 3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of February 12, 2019.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the February 12, 2019
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the February 12, 2019

Emikay Research is also available on www.emkayglobal.com, Bloomberg EMKAY<GO>, Reuters and DOWJONES. DBS Bank Ltd, DBS Vickers Securities (Singapore) Ple Ltd, its respective connected and associated corporations and affiliates are the distributors of the research report or research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore

## COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY DBS BANK LTD AS DISTRIBUTOR OF THE RESEARCH REPORT

- 1. DBS Bank Ltd., DBS HK, DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS") or their subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of 30 Apr 2018.
- 2. Neither DBS Bank Ltd nor DBS HK market makes in equity securities of the issuer(s) or company(ies) mentioned in this Research Report.

#### Compensation for investment banking services:

3. DBSVUSA, does not have its own investment banking or research department, nor has it participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months. Any US persons wishing to obtain further information, including any clarification on disclosures in this disclaimer, or to effect a transaction in any security discussed in this document should contact DBSVUSA exclusively.

#### Disclosure of previous investment recommendation produced:

4. DBS Bank Ltd. DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS"), their subsidiaries and/or other affiliates may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by DBS Bank Ltd. DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS"), their subsidiaries and/or other affiliates in the preceding 12 months.

#### RESTRICTIONS ON DISTRIBUTION

General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom.  In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and
United Kingdom	associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6th Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

## Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

Emkay Research is also available on www.emkayglobal.com, Bloomberg EMKAY<GO>, Reuters and DOWJONES. DBS Bank Ltd, DBS Vickers Securities (Singapore) Pie Ltd, its respective connected and associated corporations and affiliates are the distributors of the research reports, please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore

#### **SINGAPORE**

#### **DBS Bank Ltd**

Contact: Janice Chua

12 Marina Boulevard, Marina Bay Financial Centre Tower 3

Singapore 018982 Tel. 65-6878 8888 Fax: 65 65353 418

e-mail: equityresearch@dbs.com Company Regn. No. 196800306E

#### **THAILAND**

#### DBS Vickers Securities (Thailand) Co Ltd

Contact: Chanpen Sirithanarattanakul 989 Siam Piwat Tower Building,

9th, 14th-15th Floor

Rama 1 Road, Pathumwan, Nagkok Thailand 10330 Tel. 66 2 857 7831

Fax: 66 2 658 1269 e-mail: research@th.dbs.com

Company Regn. No 0105539127012

Securities and Exchange Commission, Thailand

#### **INDONESIA**

#### PT DBS Vickers Sekuritas (Indonesia)

Contact: Maynard Priajaya Arif

DBS Bank Tower Ciputra World 1, 32/F Jl. Prof. Dr. Satrio Kav. 3-5 Jakarta 12940, Indonesia Tel. 62 21 3003 4900

Fax: 62 21 3003 4943

e-mail: research@id.dbsvickers.com



Vishal Chandak, CA, PGPM vishal.chandak@emkayglobal.com +91 22 6612 1275

Emikay Research is also available on www.emikayglobal.com, Bloomberg EMIKAY<GO>, Reuters and DOWJONES. DBS Bank Ltd, DBS Vickers Securities (Singapore) Ple Ltd,its respective connected and associated corporations and affiliates are the distributors of the research reports, please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore